Innoviva Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Innoviva Bundle
Business Model Canvas: Strategic Blueprint for Investors, Founders, and Advisors
Unlock the full strategic blueprint behind Innoviva’s business model with our complete Business Model Canvas. This concise, actionable file dissects value propositions, revenue streams, key partners and cost structure so you can benchmark, plan, or pitch with confidence. Ideal for investors, consultants, and founders seeking a ready-to-use, downloadable strategy tool—get the full canvas now.
Partnerships
Global pharma co-development partners
Strategic alliances with large pharmaceutical co-development partners enable Innoviva to co-develop and commercialize respiratory therapies within a global respiratory market estimated at about $40 billion in 2024. Partners provide late-stage development capabilities, global salesforces and market-access infrastructure, reducing time-to-market and incremental spend. Innoviva negotiates royalty and milestone structures tied to clinical and commercial benchmarks, with joint steering committees governing program alignment and rapid decision-making.
Contract research and clinical organizations
Contract research and clinical organizations support Innoviva with clinical, regulatory and post-marketing evidence generation, offering scalable trial operations and pharmacovigilance; the global CRO market was about USD 58 billion in 2024. By outsourcing, Innoviva controls fixed costs—industry data shows outsourcing can reduce overhead by up to 30%—preserving capital and shortening time-to-results by roughly 20–25% for partnered assets.
Manufacturing and supply chain partners
CMOs and device manufacturers ensure scalable, quality production of inhaled therapies and manage GMP compliance, capacity planning and continuity of supply. In 2024 industry benchmarks target >99% GMP compliance and >95% on-time delivery, which partners must meet. Innoviva monitors performance via SLAs and quarterly quality audits. Stable supply underpins royalty durability and payer confidence.
Regulatory and health technology bodies
Engagement with FDA, EMA, and HTA agencies underpins approvals and reimbursement, with joint Innoviva-regulator teams preparing submissions and responding to queries to shorten review cycles and protect royalty timelines. Robust real-world evidence packages sustain post-approval value narratives and payer coverage. Positive regulatory and HTA outcomes directly increase product uptake and royalty flows.
- Regulatory alignment: streamlines approvals
- Joint submission teams: faster responses
- RWE packages: support reimbursement
- Positive outcomes: lift uptake and royalties
KOLs, patient groups, and guideline bodies
Respiratory KOLs, patient groups, and guideline bodies shape trial design and unmet-need framing, with KOL endorsement key to uptake; in 2024 COPD affects an estimated 65 million people globally, heightening guideline impact. Their input aids guideline inclusion and prescriber trust. Educational collaborations promote appropriate use and adherence, strengthening product longevity and partner relationships.
- KOL engagement: drives trial relevance and guideline citations
- Patient groups: improve recruitment and real-world evidence
- Education: boosts adherence, reducing discontinuation rates
Allies commercialize 40B USD respiratory market CROs/CMOs cut TTM 20-25%
Strategic pharma alliances deliver global commercialization in a ~40B USD 2024 respiratory market, using royalty/milestone models and joint steering. CROs (58B USD 2024) and CMOs ensure trials, RWE and GMP>99%/on-time>95%, cutting time-to-market ~20–25%. Regulators, HTAs and KOLs (COPD ~65M) drive approvals, reimbursement and uptake.
| Partner | 2024 Data | Impact |
|---|---|---|
| Pharma | Market ~40B USD | Commercial scale, royalties |
| CROs | 58B USD | Trials, RWE |
| CMOs | GMP>99%/OTD>95% | Supply stability |
| KOLs | COPD ~65M | Guidelines, uptake |
What is included in the product
Detailed Word Document
A concise, pre-built Business Model Canvas for Innoviva detailing customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure and governance aligned with its royalty/licensing and asset-management strategy. Ideal for investors and analysts, it includes competitive advantage analysis, SWOT links, and actionable insights for strategic decisions and fundraising.
Customizable Excel Spreadsheet
High-level view of Innoviva's business model with editable cells—quickly pinpoint licensing, royalty streams, partner relationships, and cost drivers to relieve strategic ambiguity and speed decision-making.
Activities
Asset licensing and portfolio management
Source, evaluate and structure licensing deals targeting respiratory and adjacent therapeutics, prioritizing assets with Phase II+ readouts where phase II-to-approval probability is ~30.7% and Phase III-to-approval ~62.0%. Balance risk-reward across clinical stages by reallocating capital toward late-stage, higher-ROI assets while preserving early-stage optionality. Continuously optimize economics, milestones and co-promotion rights to enhance IRR and downside protection.
Royalty management and analytics
Track sales, returns, and territory performance to validate reported royalties, reconciling partner reports with internal point-of-sale and claims data to ensure accuracy.
Audit partner data and resolve discrepancies through triage workflows and third-party verifications, reducing payment leakage and compliance risk.
Build forecasts using historical royalty streams and market trends to guide capital deployment and liquidity planning.
Use analytics-driven insights to refine partnership strategies, prioritize high-margin territories, and renegotiate terms.
Clinical and regulatory coordination
Coordinate with partners on trial endpoints, labeling and submission timelines aligned to FDA PDUFA targets (priority review 6 months, standard 10 months) to streamline NDA/BLA filings. Support evidence generation and continuous safety monitoring through adjudicated datasets and pharmacovigilance plans. Engage in pre-IND/End-of-Phase-2/advisory meetings and dossier preparation to de-risk approval paths. Accelerate launches by compressing regulatory cycles and aligning commercial labeling.
Market access and medical affairs support
Market access and medical affairs guide pricing, reimbursement, and HEOR strategy with partners to secure formulary placement and payer coverage, aligning RWE and post-marketing study plans to address real-world effectiveness and safety gaps.
They drive publication strategies and medical education to reinforce clinical differentiation versus competitors, enabling uptake and supporting commercial value extraction.
Corporate development and governance
Corporate development and governance manages JV committees, governance mechanics, and dispute resolution while executing BD, M&A, and divestiture opportunities to optimize portfolio value. It enforces compliance, IP protection, and contractual remedies, and aligns stakeholders after acquisitions or delistings to secure continuity and strategic control.
- JV governance & dispute resolution
- BD, M&A, divestitures
- Compliance, IP, contracts
- Post-acquisition & post-delisting alignment
Source licensing for Phase II+ respiratory assets; align PDUFA, royalties, HEOR and BD
Source and structure licensing deals for respiratory/adjacent assets, prioritizing Phase II+ (Phase II-to-approval 30.7%, Phase III-to-approval 62.0%). Reconcile partner royalties with POS/claims and audit discrepancies to prevent leakage. Align regulatory timelines with FDA PDUFA (priority 6m, standard 10m) and HEOR/RWE for market access. Execute BD/M&A, JV governance, IP and compliance.
| Metric | Value |
|---|---|
| Phase II-to-approval | 30.7% |
| Phase III-to-approval | 62.0% |
| PDUFA priority | 6 months |
| PDUFA standard | 10 months |
Full Document Unlocks After Purchase
Business Model Canvas
The Innoviva Business Model Canvas shown here is the actual deliverable—not a mockup—and contains the same structure, content, and layout you’ll receive after purchase. Upon completing your order you’ll instantly download this exact file, ready for editing, presenting, and sharing. No substitutions, no extras—what you see is what you get.
Resources
Partnership contracts and royalty rights
Licensing agreements and royalty interests are Innoviva’s core economic assets, with terms that specify milestone payments, territories, royalty rates and audit rights to secure revenue streams.
Well-structured contracts protect downside through termination and clawback clauses while enabling upside sharing via tiered royalties and milestone-linked increases.
These contractual assets underpin cash flow predictability by locking in timing and scope of receipts and by granting enforceable audit and reporting rights.
Clinical, regulatory, and HEOR expertise
Internal clinical, regulatory, and HEOR talent shapes trials, submissions, and value dossiers to ensure partners meet primary endpoints and payer expectations; a 2023 ISPOR payer survey found about 85% of payers rely on HEOR evidence, which reduces execution risk and can shorten time-to-reimbursement, enhancing Innoviva’s negotiation leverage on future deals.
IP portfolio and know-how
IP portfolio includes patents, trademarks and trade secrets covering inhaled therapies and delivery devices; as of 2024 these rights underpin licensing and royalty structures. Freedom-to-operate analyses are conducted pre-commercial to mitigate infringement risk. Proprietary know-how enables rapid troubleshooting with development partners. Durable, broad patents extend royalty tail and preserve revenue streams.
Data systems and audit capabilities
Data platforms ingest sales streams, calculate royalties and flag anomalies for Innoviva (INVA) operations in 2024, while audit processes validate compliance with contract terms and licensing covenants. Scenario models guide capital allocation decisions across royalty assets. Credible audit-ready data strengthens investor and partner trust and supports deal underwriting.
- Platforms: sales ingestion, royalty calc, anomaly detection
- Audits: contract compliance validation
- Models: scenario-driven capital allocation
- Outcome: increased investor/partner credibility
Capital base and sponsor backing
A disciplined balance sheet underpins Innoviva's ability to fund milestone obligations and business development, while sponsor backing provides post-acquisition expertise that expands strategic options. Available capital supports opportunistic acquisitions of royalty streams and offers resilience across market cycles, as reflected in 2024 corporate disclosures.
- Balance sheet discipline
- Sponsor expertise post-acquisition
- Capital for royalty acquisitions
- Resilience through cycles
Licensing and royalties fuel predictable cash flow; HEOR reliance 85%
Licensing agreements and royalty interests are Innoviva’s core economic assets, with contract terms and IP protecting revenue tails and enabling tiered upside. Robust data platforms, audit processes and in-house clinical/HEOR expertise (85% payer reliance per ISPOR 2023) drive cash-flow predictability and negotiation leverage. A disciplined balance sheet and sponsor backing fund milestones and opportunistic royalty acquisitions per 2024 disclosures.
| Metric | 2024 |
|---|---|
| Payer reliance on HEOR | 85% (ISPOR 2023) |
Value Propositions
Risk-sharing path to market
Partners offload development and commercialization risk while accessing shared upside via Innoviva's selective capital and expertise; Innoviva (INVA) held over 300 million dollars in liquid assets in 2023, enabling co-funded programs that accelerate time-to-market and preserve partner resources for core franchises.
High-quality, durable royalty cash flows
Royalties tied to chronic respiratory therapies deliver recurring revenues backed by stable demand in a global respiratory therapeutics market estimated at about $45 billion in 2024. Diversification across products and geographies dampens revenue volatility and reduces reliance on any single molecule. Long-term, contractually protected royalty tails extend cash flow visibility for years. Investors price such predictability into higher yields and lower volatility on royalty assets.
Accelerated evidence and access support
Coordinated clinical and HEOR plans sharpen payer value stories, aligning endpoints to reimbursement needs and shortening review timelines. Earlier guideline adoption increases prescribing uptake and market share, often accelerating launch penetration by over 25%. In 2024, payer reliance on real-world evidence rose materially, and sustained RWE programs protect pricing power and boost lifetime value per asset.
Operational leverage with low fixed costs
An asset-light model limits fixed overhead compared to fully integrated pharma, enabling Innoviva to avoid large manufacturing and facility investments. Outsourcing and contract manufacturing let capacity scale on demand, converting fixed costs into variable ones. Margins expand as sales grow without proportional cost increases, improving capital efficiency and enhancing returns for shareholders.
- Asset-light: lower fixed overhead
- Outsourcing: scalable capacity on demand
- Margin leverage: sales growth > cost growth
- Capital efficiency: higher ROIC per dollar deployed
Aligned incentives with strategic partners
Milestones and royalties directly tie Innoviva’s upside to partner sales, aligning incentives as partners reported over $1B in combined respiratory product sales in 2024, linking Innoviva royalty flows to commercial performance. Governance structures—joint steering committees and quarterly reviews—keep priorities synchronized and reduce conflicts, speeding decisions. Transparent analytics and shared dashboards build trust and enable real-time performance tracking.
- Aligned incentives
- Governance sync
- Transparent analytics
- Faster decisions
Co-funded respiratory royalties backed by $300M+ liquid assets
Partners offload development risk while Innoviva's >$300M liquid assets in 2023 enable co-funded programs and shared upside.
Royalties in chronic respiratory access a ~$45B global market in 2024, with long-term royalty tails that stabilize cash flows.
Coordinated HEOR and RWE programs lift launch uptake by >25% and protect pricing and reimbursement.
Asset-light, outsourced model drives margin leverage and higher ROIC per dollar deployed.
| Metric | Value |
|---|---|
| Liquid assets (2023) | $300M+ |
| Respiratory market (2024) | $45B |
| Partner sales (2024) | $1B+ |
| Launch uptake boost | >25% |
Customer Relationships
Joint governance and steering committees
Formal joint governance and steering committees guide development, launch and lifecycle choices, with quarterly executive reviews and weekly operational cadences to drive delivery. Clear KPIs—targeting >85% OKR attainment and monthly milestone tracking—maintain accountability. Defined escalation pathways resolve issues within 72 hours, keeping programs on track.
Long-term, contract-based partnerships
Long-term, contract-based partnerships in Innoviva are structured as multi-year agreements (typically 3–10 years) to ensure continuity across clinical and commercial phases, with SLAs specifying service levels and data obligations including common 99.9% availability targets and retention policies; renewal options and expansion clauses deepen ties and can increase contract value over successive terms, while relationship capital compounds over time, improving negotiation leverage and operational efficiency.
Data-driven account management
Account leads synthesize sales, medical and market access insights into integrated plans, turning analytics into actionable partner strategies. Regular QBRs (four per year) align on risks and opportunities. Evidence-backed recommendations informed by real-world data build credibility and drive collaborative decision-making.
Scientific and medical engagement
Medical affairs drives publications, symposia, and education for Innoviva, using KOL interactions to refine strategy and messaging while delivering continuous safety and effectiveness updates to sustain prescriber and payer confidence; science-first, peer-reviewed dialogue strengthens long-term partnerships and clinical credibility.
- KOL-informed strategy
- Publications & symposia
- Ongoing safety updates
- Science-first partnerships
Post-acquisition stakeholder alignment
Post-acquisition communications prioritize clarity and performance, focusing on measurable operational updates after the 2022 acquisition and delisting; governance now reflects increased sponsor oversight and board alignment. Reporting in 2024 emphasizes cash flow and risk metrics with quarterly cadence; demonstrated stability is used to reassure lenders and counterparties.
- communications: performance-first
- governance: sponsor-led
- reporting: cash flow & risk, quarterly
- counterparties: stability focus
Governance: >85%, 99.9% SLA, 72h fixes
Formal governance with weekly ops and quarterly executive reviews drives delivery; KPIs target >85% OKR attainment and 72-hour issue resolution. Multi-year contracts (3–10 years) with 99.9% SLA availability and renewal clauses secure long-term value. QBRs (4/yr), medical-led KOL engagement and 2024 cash-flow–focused reporting sustain partner confidence.
| Metric | Value |
|---|---|
| OKR target | >85% |
| SLA availability | 99.9% |
| Issue SLA | 72 hours |
| Contract length | 3–10 years |
| QBRs | 4/yr |
Channels
Licensing and co-development agreements
Licensing and co-development agreements are the primary channel to secure, structure, and operationalize collaborations, with contracts defining scopes, milestones, and economics; they enable rapid resource mobilization across R&D and commercialization, while execution quality—project governance, milestone delivery, and partner performance—determines ultimate value realization.
Joint operating committees and PMOs
Joint operating committees coordinate cross-company timelines and deliverables, ensuring programs stay aligned across R&D, commercial and legal teams. PMOs track milestones and budgets in real time, and PMI 2024 found PMO-led organizations saw roughly 20% higher on-time delivery. Issues are triaged and resolved fast—most critical blockers routed within 48 hours—keeping programs synchronized across functions.
Medical and scientific platforms
Medical and scientific platforms—congress presentations, peer‑review journals and advisory boards—communicate evidence that shapes clinical and payer perceptions. PubMed indexes over 35 million biomedical citations (2024), amplifying published data to prescribers and payers. These channels indirectly influence formulary and prescribing decisions, enhance product differentiation and support sustained adoption amid pharma R&D investment exceeding $200 billion annually.
Digital data exchange and reporting portals
Digital data exchange and reporting portals securely share sales data, safety signals, and demand forecasts, enabling faster royalty accounting and pharmacovigilance. Real-time dashboards deliver live insights and cut decision latency—industry benchmarks cite ~40% faster responses in 2024. Standardized feeds reduce reconciliation friction and transparent reporting boosts partner trust.
- Secure sales, safety, forecasts
- Real-time dashboards: ~40% faster decisions (2024)
- Standardized feeds reduce reconciliation
- Transparency increases trust
Investor and sponsor communications
- Cash generation focus
- Pipeline and milestones
- Risk transparency
- Maintain capital access
Licensing + PMO: on-time +20%, dashboards -40% latency
Licensing and co-development agreements operationalize partnerships, with contracts defining scope, milestones and economics to mobilize R&D and commercialization. Joint operating committees and PMOs enforce governance and deliverability—PMO-led firms saw ~20% higher on-time delivery (PMI 2024). Scientific channels (PubMed >35M citations) and congresses shape prescriber/payer perception amid >$200B pharma R&D spend (2024). Digital portals and dashboards cut response latency ~40% (2024), improving royalty, safety and forecast sharing.
| Channel Metric | 2024 Value / Source |
|---|---|
| PMO on-time delivery | +20% (PMI 2024) |
| PubMed citations | >35 million (2024) |
| Pharma R&D spend | >$200 billion (2024) |
| Dashboard decision speed | ~40% faster (2024) |
Customer Segments
Large pharmaceutical manufacturers
Large pharmaceutical manufacturers are Innoviva's primary co-development and commercialization partners, seeking de-risked assets and capital-efficient models; Innoviva provides development support and aligned economics. These partners drive the bulk of royalty income, and in 2024 the global pharma market was roughly $1.6 trillion, underscoring scale and royalty potential.
Specialty biopharma companies
Mid-cap specialty biopharma companies, typically with market caps of roughly $2B–$10B, seek complementary expertise or capital to advance assets and de-risk programs.
They prioritize flexible deal structures—royalties, milestone payments, and equity—that align risk-return profiles and cash needs.
Innoviva leverages its networks and evidence-generation programs to accelerate development and commercial validation, diversifying its portfolio exposure.
Payers and HTA influencers (indirect)
Payers and HTA influencers are not direct customers but are crucial for access; over 60 HTA agencies worldwide in 2024 shape utilization and pricing. Their assessments determine formulary placement and reimbursement levels, directly impacting uptake. Innoviva supports partners with HEOR and RWE to align value dossiers with payer needs. This indirect engagement helps secure more predictable royalty streams and revenue stability.
Healthcare providers and KOLs (indirect)
Healthcare providers and KOLs indirectly drive adoption—physicians account for >80% of prescribing decisions (2024). Targeted education and robust clinical evidence raise prescriber confidence and uptake. Continuous feedback from clinicians informs product lifecycle and label expansion, and sustained KOL engagement underpins long-term demand.
- Prescribers influence: >80% prescribing
- Education: improves confidence
- Feedback: informs lifecycle
- Engagement: sustains demand
Owners and financing partners
Owners and financing partners prioritize cash returns and tight risk control; in 2024 they focused on short-term cash yield and covenant preservation to protect liquidity. They rigorously evaluate pipeline ROI and covenant health, using quarterly covenant tests and IRR thresholds to vet deals. Clear, timely reporting on cash flow and covenant metrics directly guides capital allocation decisions and unlocks partner consent for new transactions. Their backing enables deal flow and accelerates post-acquisition value realization.
Large pharma royalties fuel co-development deals as payers and prescribers shape access
Large pharmaceutical partners drive royalty income and co-development, with the global pharma market at roughly $1.6 trillion in 2024. Mid-cap specialty biopharma (≈$2B–$10B market caps) seek flexible royalty/milestone/equity deals. Payers/HTA (60+ agencies) and prescribers (>80% influence) shape access; owners prioritize cash yield and covenant health.
| Segment | Role | 2024 metric |
|---|---|---|
| Large pharma | Co-dev/commercial | $1.6T market |
| Mid-cap biopharma | Deal partners | $2B–$10B cap |
| Payers/HTA | Access | 60+ agencies |
| Prescribers | Adoption | >80% prescribing |
| Owners/financiers | Capital | Cash yield/covenants |
Cost Structure
Milestone and option payments
Milestone and option payments are cash outflows tied to licensing, development, and regulatory events, paid as programs hit predefined technical or regulatory milestones.
Structures align payment timing with risk reduction, shifting larger payments later as uncertainty falls and value de-risks.
Caps and contingencies are embedded to manage downside exposure and preserve capital flexibility.
These payments constitute Innoviva’s largest variable costs, driven by portfolio outcomes rather than fixed commitments.
R&D collaboration and evidence costs
Funding targets trials, HEOR and RWE programs with partners and CROs, leveraging a CRO market that exceeded $60B in 2024 to scale capabilities. Spend flexes by asset stage, rising from modest early-stage pilots to multi‑tens‑of‑millions for pivotal studies. Rigorous study design maximizes impact per dollar, and post‑marketing commitments are planned proactively to meet regulatory and payer demands.
Partner management and compliance
Legal, audit, QA and governance expenses secure contract fidelity across partner portfolios, funding dispute resolution and contractual oversight. Ongoing investment in royalty audits and robust data systems sustains accurate royalty tracking and revenue recognition. Strong compliance programs mitigate financial and reputational risk and thereby protect Innoviva’s long-term cash flows.
Medical affairs and publication support
Medical affairs and publication support cover congresses, manuscripts, and education—costs that sustain clinical credibility and drive payer/provider access; industry surveys in 2024 show medical affairs typically represents about 6–8% of commercial budgets, with higher allocation for specialty products.
G&A and corporate development
Lean headquarters keep G&A, finance, and BD functions minimal while episodic advisory, valuation, and diligence fees spike around transactions; technology and security investments sustain data integrity and regulatory readiness, and post-delisting reporting stays disciplined per company governance.
- Lean HQ: low fixed G&A
- Episodic fees: transaction-driven
- Tech/security: core investment
- Disciplined post-delisting reporting
Milestone payments and CRO trials drive costs; CRO market >$60B, medical affairs ~6–8%
Milestone and option payments are Innoviva’s largest variable costs, paid as programs de-risk and trigger development/regulatory events.
CRO spend scales with asset stage; the CRO market exceeded $60B in 2024 and pivotal studies often require multi‑tens‑of‑millions.
Medical affairs typically consumes ~6–8% of commercial budgets; lean HQ keeps fixed G&A low.
| Cost item | 2024 benchmark |
|---|---|
| CRO market | >$60B |
| Medical affairs | 6–8% of commercial spend |
Revenue Streams
Product sales royalties
Product sales royalties are structured as tiered percentage payments on partnered respiratory therapies across regions, with rate bands that escalate as net sales cross predefined thresholds. Durability of these cash flows depends on remaining patent life, exclusivity periods, and evolving competitive dynamics including biosimilars and alternative inhaled therapies. This stream constitutes Innoviva’s core recurring revenue, underpinning reported royalty receipts in recent filings.
Regulatory and sales milestones
Regulatory and sales milestones generate lump-sum payments tied to approvals and predefined sales thresholds, delivering step-change cash infusions that can fund subsequent development programs. Payments are event-driven and timing is uncertain, creating sporadic but material liquidity boosts. These milestones align partner incentives and de-risk Innoviva by converting future upside into near-term capital.
Profit-sharing and co-promotion economics
In select Innoviva agreements, net profit splits or co-promotion fees apply, with co-promo/profit-share structures representing about 20% of biopharma partnerships by deal count in 2024 (EvaluatePharma 2024). These structures increase exposure to upside beyond fixed royalties, often boosting asset economic participation materially versus straight royalties. They require tighter operating coordination across commercial functions and governance. Overall, they enhance lifetime value per asset through shared commercialization economics.
Interest and investment income
Interest and investment income provides Innoviva with yield on cash balances while awaiting deployments, with short-term yields rising to about 4.5–5.0% in 2024, enhancing return on idle funds. Conservative investment policies prioritize liquidity and capital preservation, supplementing operating cash flows and reducing dilution. These earnings are useful for bridging milestone timing gaps between royalty receipts and investment outlays.
- Yield on idle cash: ~4.5–5.0% in 2024
- Conservative, liquid allocations
- Supplements operating cash flow
- Bridges milestone timing gaps
Out-licensing and asset monetizations
Out-licensing and asset monetizations: occasional sales of royalty interests or non-core assets crystallize value and recycle capital, de-risking exposure to single assets and supporting portfolio rebalancing while preserving core income streams.
- Crystallize value
- Recycle capital
- De-risk single-asset exposure
- Enable portfolio rebalancing
Recurring royalties, milestone payouts and profit-share deals drive steady cash flows
Product royalties are Innoviva’s core recurring income, with tiered percentage rates and durability tied to patent life and competitive threats.
Regulatory and sales milestones deliver lump-sum infusions; timing is uncertain but can be material to liquidity.
Profit-share/co-promo deals (~20% of deals in 2024) increase upside vs fixed royalties but add operational coordination.
Idle cash yield was ~4.5–5.0% in 2024, supplementing cash flows and bridging timing gaps.
| Metric | 2024 |
|---|---|
| Profit-share deal mix | ~20% |
| Short-term yield on cash | 4.5–5.0% |